Literature DB >> 12358367

Long-term observation and management of resolving infantile idiopathic scoliosis a 25-year follow-up.

O Diedrich1, A von Strempel, M Schloz, O Schmitt, C N Kraft.   

Abstract

Of 42 patients with resolving infantile idiopathic scoliosis, 34 were followed up for more than 25 years. Twenty had been primarily treated in a plaster bed and 14 by physiotherapy. The mean angle of the curve at presentation was 17 degrees and at follow-up it was 5 degrees. No patient had significant progression of the scoliosis during the growth spurt. When adults few had back pain or an increased disability score and there was no interference with work or social activities. The rib-vertebra angle difference proved to be an essential radiological sign when distinguishing resolving from progressive infantile idiopathic scoliosis. There was no advantage of plaster over physiotherapy with regard to either the time to resolution or the functional outcome. Treatment of resolving infantile idiopathic scoliosis in a plaster bed is therefore now outdated.

Entities:  

Mesh:

Year:  2002        PMID: 12358367     DOI: 10.1302/0301-620x.84b7.13005

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  3 in total

1.  Scoliosis in patients with Chiari malformation type I.

Authors:  Mohammad Hassan A Noureldine; Nir Shimony; George I Jallo; Mari L Groves
Journal:  Childs Nerv Syst       Date:  2019-07-24       Impact factor: 1.475

Review 2.  Epidemiology of adolescent idiopathic scoliosis.

Authors:  Markus Rafael Konieczny; Hüsseyin Senyurt; Rüdiger Krauspe
Journal:  J Child Orthop       Date:  2012-12-11       Impact factor: 1.548

3.  Rib-vertebral angle measurements predict brace treatment outcome in Risser grade 0 and premenarchal girls with adolescent idiopathic scoliosis.

Authors:  Xu Sun; Qi Ding; Shifu Sha; Saihu Mao; Feng Zhu; Zezhang Zhu; Bangping Qian; Bin Wang; Jack C Y Cheng; Yong Qiu
Journal:  Eur Spine J       Date:  2016-01-23       Impact factor: 3.134

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.